The case of the missing PD-L1: UCSF sleuths devise a new ‘tumor cell vaccine’ and a checkpoint strategy that could surprise you
It will come as no surprise to anyone watching the I/O market boom that PD-1/L1 drugs may be amazingly effective, but for only about 1 in 4 patents. In certain types of cancer, it’s much worse.
That 1 in 4 ratio has created a multibillion-dollar business — virtually overnight in biopharma terms. But it has focused an amazing amount of attention on the other 3 who are missing out.
Starting from that premise, a team of investigators at UCSF wanted to find out why some cancer cells had less of the PD-L1 protein that are displayed on the cell surface and used to cloak themselves from an immune response.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.